Spark Therapeutics Inc (ONCE) and Other Profitable Healthcare Picks of Casdin Capital

Then there’s bluebird bio Inc (NASDAQ:BLUE), which was represented in Casdin’s equity portfolio by a $5.30 million stake containing 122,500 shares. Among the stocks covered in this article, bluebird registered the highest gains, as it appreciated by 56.57% between July and September, although it gave up the gains in the following months and is only 10% in the green year-to-date. At the end of the second quarter, a total of 21 of the hedge funds tracked by Insider Monkey were bullish on this stock. Among them, Samuel Isaly’s OrbiMed Advisors  was the largest shareholder bluebird bio Inc (NASDAQ:BLUE), worth close to $51.3 million. The second most bullish fund was Great Point Partners, led by Jeffrey Jay and David Kroin, holding a $21.6 million position. Some other professional money managers that were bullish on bluebird bio Inc (NASDAQ:BLUE) consist of James E. Flynn’s Deerfield Management, Julian Baker and Felix Baker’s Baker Bros. Advisors and Dmitry Balyasny’s Balyasny Asset Management.

Finally, Evolent Health Inc (NYSE:EVH) was a new position in Casdin’s equity portfolio as the fund added 239,500 shares worth $5.60 million in the second quarter. In the following three months, the stock gained 28.23%. During the second quarter, the number of funds followed by our team remained unchanged at seven. Of the funds tracked by Insider Monkey, Pennant Capital Management, led by Alan Fournier, reported a 25.7 million position in Evolent Health Inc (NYSE:EVH). It was followed by Joseph Edelman’s Perceptive Advisors with a $16.8 million position. Some other peers with similar optimism about Evolent Health Inc (NYSE:EVH) comprise Richard Driehaus’s Driehaus Capital and Israel Englander’s Millennium Management.

Disclosure: none